Champignon Brands (CSE: SHRM) this morning announced that it has named Dr Roger McIntyre as CEO of the firm effective immediately. Gareth Birdsall has relinquished his role to Dr McIntyre, and will continue to serve on the firms board of directors.
Dr Roger McIntyre is an expert in the field of psychedelics, and is known as the first person within Canada to successfully launch a treatment center for persons with mood disorders, referred to as the Canadian Rapid Treatment Centre of Excellence (CRTCE), which utilizes ketamine and psychedelic based treatments.
McIntyre currently holds a number of professional positions in relation to his field of study, which includes Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network. His other roles include executive directorships, chair positions, and professorships at numerous well respected global universities and foundations.
Gareth Birdsall, the former CEO of Champignon Brands will remain with the firm in the role as a director. The company has also indicated that it is considering changing its name to better reflect its diverse business lines and operating subsidiaries.
Champignon Brands last traded at $1.00 on the CSE.
FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.